

Uniklinik RWTH Aachen to present at first of its kind global summit on precision diagnosis for prostate cancer

Aachen, GERMANY, 14.07.2016 – The organizers of September's First Global Summit on Precision Diagnosis for Prostate Cancer today announced that Dr. Christiane K. Kuhl, MD, Professor and Chair, Department of Diagnostic and Interventional Radiology, University of Aachen, a leading authority in oncological imaging and interventional oncology, has agreed to participate as a featured speaker and a member of the Summit's consensus-building expert panel.

The mission of this Summit—set for September 16-18 in Boston—is to educate key stakeholders about the about the state-of-the-art and emerging advances in prostate diagnostics, and their groundbreaking impact on precision care, including personalized approaches to screening, early detection, risk assessment and treatment.

For the first time, this Summit will bring together the key multi-disciplinary experts in the development, research and clinical implementation of biomarkers, imaging, genetics, genomics and other precision diagnostics, in order to bridge the existing inter-disciplinary gaps, and to develop a consensus-based future vision for precision care and educational and scientific strategy for its realization.

"We are thrilled that Dr. Kuhl is among our outstanding speakers," said Dr. Faina Shtern, President & CEO of AdMeTech Foundation, and organizer of the Summit. "University of Aachen has been a longstanding leader in medicine, and Dr. Kuhl will bring a critical perspective to the First Global Summit on Precision Diagnosis for Prostate Cancer. With her assistance, we will review the key role of precision diagnostics in giving every man the best chance of precision, personalized prostate cancer care."

Dr. Kuhl belongs to a number of prestigious subspecialty and international societies such as the Radiological Society of North America (RSNA), the International Society of Magnetic Resonance in Medicine (ISMRM), and the American Society of Clinical Oncology (ASCO). She is also a member of the 'Working Group on Breast MRI' at the National Cancer Institute, Bethesda, Maryland, US, and member of the Breast Section of ACRIN (American College of Radiology Imaging Network).

The Summit is a key part of AdMeTech Foundation's multi-faceted, statewide campaign, which has been creating a Massachusetts model of national and international leadership in prostate cancer research, education, and awareness.

For more information on the First Global Summit on Precision Diagnosis for Prostate Cancer, visit <u>www.admetech.org/summit</u>.



About AdMeTech Foundation

A 501(c)(3) nonprofit organization based in Boston, MA, AdMeTech Foundation established the Manogram® Project to create and expedite advancement of diagnostic tools for prostate cancer akin to life-saving mammograms. The Manogram® Project provides international leadership for groundbreaking programs in research, education, awareness and advocacy in order to advance early detection and treatment, which are critical for saving lives (www.admetech.org).

Contact:

Uniklinik RWTH Aachen Dr. Mathias Brandstädter Leitung Unternehmenskommunikation Pauwelsstraße 30 52074 Aachen Telefon: 0241 80-89893 Fax: 0241 80-3389893 mbrandstaedter@ukaachen.de

About the Uniklinik RWTH Aachen (AöR)

The Uniklinik RWTH Aachen is a modern centre for high performance medicine. Under its roof are combined patientoriented medical treatment, efficient teaching and innovative research on an international level. The 34 clinics, 28 institutes and five interdisciplinary units cover the entire spectrum of modern medicine. Highly qualified teams of physicians, nurses and researchers are competently committed and dedicated to the health of our patients. The proximity of medical treatment, research and teaching offers the best requirements for an intensive interdisciplinary exchange and close clinical and academic integration. Approximately 1,400 beds are available for in-patient medical care. Yearly more than 40,000 in-patients and approx. 190,000 ambulatory patients benefit from the highest standards of medical treatment.